EPISODE · Sep 18, 2025 · 32 MIN
Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Breast Cancer
from Keeping Current CME
More options, more questions. Get clarity on patient selection and optimizing adjuvant cyclin-dependent kinase cyclin-dependent kinase (CDK)4/6 inhibitor therapy. Credit available for this activity expires: 9/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002908?ecd=bdc_podcast_libsyn_mscpedu
Embed this episode
Ready to play
Expert Perspectives on the Latest Clinical Trial Updates in HR-Positive, HER2-Negative Early Breast Cancer
0:00
32:07
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Keeping Current CME?
This episode is 32 minutes long.
When was this Keeping Current CME episode published?
This episode was published on September 18, 2025.
Can I download this Keeping Current CME episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!